Thursday, June 10, 2021 7:02:01 AM
VRNA...$7.32...on the Gappa...Psar flipped Bullish yesterday...Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company)
Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties
Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China...https://www.otcmarkets.com/stock/VRNA/news/story?e&id=1919123 ...Should be a great trader today...imo...we shall see...:partying_face:
$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company)
Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties
Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China...https://www.otcmarkets.com/stock/VRNA/news/story?e&id=1919123 ...Should be a great trader today...imo...we shall see...:partying_face:
Realized Gains = Certainty...Unrealized Gains = Meaningless...
Recent VRNA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:45:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:43:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:41:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:40:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:35:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:32:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:31:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/08/2025 08:30:17 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 10/07/2025 05:03:40 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 10/07/2025 04:59:34 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 10/07/2025 04:55:41 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 10/07/2025 12:56:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2025 11:03:44 AM
- Merck Completes Acquisition of Verona Pharma • Business Wire • 10/07/2025 10:45:00 AM
- Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales • GlobeNewswire Inc. • 10/06/2025 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2025 08:20:48 PM
- Shareholders of Verona Pharma Approve Proposed Acquisition by Merck • GlobeNewswire Inc. • 09/24/2025 08:05:00 PM
- Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025 • GlobeNewswire Inc. • 09/16/2025 10:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/10/2025 09:00:20 PM
